

Orthocell presents at Stem Cell and Regenerative Medicine Congress in London

- Orthocell presents as invited speakers its clinical data and pipeline opportunities at the World Stem Cell and Regenerative Medicine Congress in London
- Paper entitled *Cells, Scaffolds and Bioreactors for the Regeneration of Human Tendons* well received
- Generation of human tendon outside the body a key technology breakthrough

Perth, Australia; 25 May 2015: Regenerative medicine company Orthocell Limited is pleased to announce it presented as invited speakers a paper entitled *Cells, Scaffolds and Bioreactors for the Regeneration of Human Tendons* at the World Stem Cells and Regenerative Medicine Congress, a leading international regenerative medicine conference, in London.

Orthocell's current and future approaches to the regeneration of tendon tissue were presented with particular focus on the recent breakthrough by the Company in demonstrating its new technology to grow human tendons outside of the body (OCC announcement First Human Tendons Grown in Laboratory, Nov 6, 2014). Orthocell also presented the recently published successful 4.5 year follow up of its Ortho-ATI™ injection for regeneration of degenerate tendons.

Orthocell Managing Director Mr. Paul Anderson said: "As invited speakers at a significant global forum, we continue to demonstrate the world-leading character of our tendon regeneration work and the significant commercial interest in our mobility enhancing therapies.

"The breakthrough of growing functioning and healthy tendon outside the body was well received and positions Orthocell as one of the leading global companies in the musculoskeletal regenerative space."

The conference was attended by leading researchers, clinicians, companies and financiers and is held annually in London.

"This is the second time we have been invited to present at the conference and it is a pleasure to return with more positive clinical data, groundbreaking tissue engineering approaches and significant milestones achieved," said Mr. Anderson.

For more information, please contact:

General enquiries Investor Relations

Rebecca Wilson

Buchan Consulting

P: 0417 382 391

E: rwilson@buchanwe.com.au

Paul Anderson

Orthocell Limited, Managing Director

P: (08) 9360 2888

E: paulanderson@orthocell.com.au

Media enquiries

Gavin Lower

Buchan Consulting

P: (03) 8866 1215 / 0414 796 726

E: glower@buchanwe.com.au

About Orthocell Limited

Orthocell is the world's leading musculoskeletal regenerative medicine company which is focused on addressing the mobility challenge facing our ageing population. Orthocell is developing products for a variety of tendon, cartilage and soft tissue injuries and the portfolio includes TGA-approved stem cell therapies Autologous Tenocyte Implantation (Ortho-ATI™) for tendon regeneration and Autologous Chondrocyte Implantation (Ortho-ACI™) for cartilage repair. The Company's other major product is Celgro™, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications and is being readied for first regulatory approvals in the coming 12 months.